Cellectar Biosc (CLRB)

$0.29 -0.07 (-20.16%)
Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
EvenBetter99
EvenBetter99 Sep. 6 at 11:31 AM
$CLRB Platform That Finds The β€œAchilles Heel” of Cancer Cells πŸ’ͺπŸ’ͺπŸ’ͺ
1 Β· Reply
EvenBetter99
EvenBetter99 Aug. 29 at 6:26 PM
$CLRB USD 200 per share is an easy target, Look at their radiopharma tech and pipeline ☝️πŸ’ͺπŸ’ͺπŸ’ͺ
3 Β· Reply
Sloan88
Sloan88 Aug. 27 at 12:41 PM
$CLRB I’m pretty sure I started a movementπŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ˜‚πŸ˜‚πŸ˜‚πŸ˜‚ #1sharepumpclubπŸš€πŸš€πŸš€πŸš€
2 Β· Reply
Sloan88
Sloan88 Aug. 25 at 6:30 PM
$CLRB if you see a $2.88 pop in the morning it’s most likely me makes me feel good for a few hoursπŸ€·πŸ»β€β™‚οΈπŸ€·πŸ»β€β™‚οΈπŸ€·πŸ»β€β™‚οΈplus I’m up over 100k last 60 days and now 10k share club memberπŸš€πŸš€πŸš€πŸš€πŸš€
2 Β· Reply
decdfinanz
decdfinanz Aug. 25 at 11:13 AM
$CLRB Anyone knowing why this is up 15% in pre-market? 🀨🧐
2 Β· Reply
EvenBetter99
EvenBetter99 Aug. 21 at 1:39 PM
$CLRB CLRB is a "Strong Buy." πŸš€πŸš€πŸš€ Its blood cancer drug brings joy with a 61.8% major response rate and 17.8 months of relief for patients.πŸ’ͺπŸ’ͺ Financially, it is incredibly safe. A massive $140M funding lifeline plus $34M cash in the bank fully funds operations into 2027. Wall Street adores this stock, predicting a beautiful 342% upside with an $11.50 target price.πŸš€πŸš€ With an FDA submission set for mid-2027, this company is a bright, winning choice!πŸ’ͺπŸ’ͺ
1 Β· Reply
Polaris2024
Polaris2024 Aug. 21 at 10:53 AM
$CLRB This company cannot get there act together. I have lost $100,000’s on this stock and the same scenario always plays out. Never gets through the FDA
0 Β· Reply
CantNameThatTune
CantNameThatTune Aug. 19 at 12:00 PM
$TNON $CLRB The point I was trying to make is... If CLRB has ALL that goodness going on with so many targets $10-$25 and still down under $3 then... TNON has no business being double digits
1 Β· Reply
CantNameThatTune
CantNameThatTune Aug. 19 at 11:46 AM
$TNON Sometimes I'm left to wonder what on earth people are possibly thinking. There is a stock $CLRB sitting on the cusp on Ph 2 results anytime that will give clear indication their current lead indication will be a "Best in World" treatment plan that will lead to immediate FDA approval. It has a dozen price targets from $10 - $25 What is TNON news? No new sales. Is anyone even buying Catamaran? $100 million shelf offering because no one is buying. It's the one running over $10? Huh?
0 Β· Reply
Sloan88
Sloan88 Aug. 14 at 7:44 PM
$CLRB we have a new Mag 7
2 Β· Reply
Latest News on CLRB
Cellectar Biosciences Transcript: Study update

Aug 18, 2026, 11:30 AM EDT - 26 days ago

Cellectar Biosciences Transcript: Study update

Cellectar Biosciences Slides: Study update

Aug 18, 2026, 11:30 AM EDT - 26 days ago

Cellectar Biosciences Slides: Study update

Cellectar Biosciences Slides: Corporate presentation

Aug 18, 2026, 7:00 AM EDT - 26 days ago

Cellectar Biosciences Slides: Corporate presentation

Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)

2026-08-17T08:00:50.000Z - 27 days ago

Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)

Cellectar Biosciences Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

Cellectar Biosciences Earnings Call Transcript: Q2 2026

Cellectar Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

Cellectar Biosciences Quarterly report: Q2 2026

Cellectar Biosciences Earnings release: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

Cellectar Biosciences Earnings release: Q2 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Aug 13, 2026, 7:15 AM EDT - 4 weeks ago

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Jul 30, 2026, 8:05 AM EDT - 6 weeks ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Cellectar Biosciences Slides: Corporate presentation

Jul 21, 2026, 7:00 AM EDT - 7 weeks ago

Cellectar Biosciences Slides: Corporate presentation

Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results

2026-07-15T12:05:38.000Z - 2 months ago

Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Jul 15, 2026, 7:30 AM EDT - 2 months ago

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Cellectar Biosciences initiated with a Buy at Brookline

2026-07-12T21:55:11.000Z - 2 months ago

Cellectar Biosciences initiated with a Buy at Brookline

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r WaldenstrΓΆm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Jun 1, 2026, 8:05 AM EDT - 3 months ago

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r WaldenstrΓΆm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Cellectar Biosciences Slides: Corporate presentation

Jun 1, 2026, 7:00 AM EDT - 3 months ago

Cellectar Biosciences Slides: Corporate presentation

Cellectar Biosciences Registration statement: Registration filing

May 29, 2026, 8:00 AM EDT - 3 months ago

Cellectar Biosciences Registration statement: Registration filing

Cellectar Biosciences Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 3 months ago

Cellectar Biosciences Proxy statement: Proxy filing

Cellectar Biosciences Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 3 months ago

Cellectar Biosciences Proxy statement: Proxy filing

Cellectar Biosciences files to sell 51.21M shares of common stock for holders

2026-05-19T21:10:11.000Z - 3 months ago

Cellectar Biosciences files to sell 51.21M shares of common stock for holders

Cellectar Biosciences Registration statement: Registration filing

May 19, 2026, 8:00 AM EDT - 3 months ago

Cellectar Biosciences Registration statement: Registration filing

Cellectar Biosciences Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 3 months ago

Cellectar Biosciences Proxy statement: Proxy filing

Cellectar Biosciences assumed with a Buy at Ladenburg

2026-05-15T15:14:00.000Z - 4 months ago

Cellectar Biosciences assumed with a Buy at Ladenburg

Cellectar Biosciences Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Cellectar Biosciences Earnings Call Transcript: Q1 2026

Cellectar Biosciences Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Cellectar Biosciences Quarterly report: Q1 2026

Cellectar Biosciences Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Cellectar Biosciences Earnings release: Q1 2026

Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)

2026-05-14T12:04:17.000Z - 4 months ago

Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 14, 2026, 7:15 AM EDT - 4 months ago

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

May 11, 2026, 8:05 AM EDT - 4 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital

2026-05-05T14:55:41.000Z - 4 months ago

Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital

Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint

2026-05-05T13:23:40.000Z - 4 months ago

Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r WaldenstrΓΆm Macroglobulinemia

May 5, 2026, 7:10 AM EDT - 4 months ago

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r WaldenstrΓΆm Macroglobulinemia

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

May 5, 2026, 7:00 AM EDT - 4 months ago

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

Cellectar Biosciences enrolls first patient in CLR 121125 trial

2026-04-14T13:28:41.000Z - 5 months ago

Cellectar Biosciences enrolls first patient in CLR 121125 trial

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

Apr 14, 2026, 8:35 AM EDT - 5 months ago

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

Cellectar Biosciences upgraded to Buy from Hold at Maxim

2026-03-10T11:45:55.000Z - 6 months ago

Cellectar Biosciences upgraded to Buy from Hold at Maxim

Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital

2026-03-04T14:50:33.000Z - 6 months ago

Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital

Cellectar Biosciences Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Cellectar Biosciences Earnings Call Transcript: Q4 2025

Cellectar Biosciences Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Cellectar Biosciences Earnings release: Q4 2025

Cellectar Biosciences Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Cellectar Biosciences Annual report: Q4 2025

Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year

2026-03-04T12:16:54.000Z - 6 months ago

Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Mar 4, 2026, 7:15 AM EST - 6 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Cellectar Biosciences Slides: corporate presentation

Mar 4, 2026, 7:00 AM EST - 6 months ago

Cellectar Biosciences Slides: corporate presentation

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Feb 25, 2026, 8:05 AM EST - 6 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Cellectar Biosciences expands global intellectual property estate

2026-02-17T13:25:24.000Z - 6 months ago

Cellectar Biosciences expands global intellectual property estate

Cellectar Biosciences Expands Global Intellectual Property Estate

Feb 17, 2026, 8:05 AM EST - 6 months ago

Cellectar Biosciences Expands Global Intellectual Property Estate

Cellectar Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 8 months ago

Cellectar Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Cellectar Biosciences Transcript: Biotech Showcase 2026

Jan 13, 2026, 4:30 PM EST - 8 months ago

Cellectar Biosciences Transcript: Biotech Showcase 2026

Cellectar Biosciences Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Cellectar Biosciences Slides: Corporate presentation

Cellectar Biosciences to highlight company’s 2026 strategic initiatives

2026-01-09T13:16:25.000Z - 8 months ago

Cellectar Biosciences to highlight company’s 2026 strategic initiatives

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

Jan 9, 2026, 8:05 AM EST - 8 months ago

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

Cellectar Biosciences announces supply agreement with Ionetix

2025-12-16T13:11:21.000Z - 9 months ago

Cellectar Biosciences announces supply agreement with Ionetix

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Dec 16, 2025, 8:05 AM EST - 9 months ago

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Cellectar Biosciences Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:30 AM EST - 10 months ago

Cellectar Biosciences Earnings Call Transcript: Q3 2025

Cellectar Biosciences Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 10 months ago

Cellectar Biosciences Earnings release: Q3 2025

Cellectar Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 8:30 AM EST - 10 months ago

Cellectar Biosciences Quarterly report: Q3 2025

Cellectar Biosciences reports Q3 EPS ($1.41), consensus ($2.53)

2025-11-13T12:25:57.000Z - 10 months ago

Cellectar Biosciences reports Q3 EPS ($1.41), consensus ($2.53)

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:20 AM EST - 10 months ago

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cellectar Biosciences receives RPDD from U.S. FDA for iopofosine I 131

2025-10-27T12:42:21.000Z - 10 months ago

Cellectar Biosciences receives RPDD from U.S. FDA for iopofosine I 131

Cellectar Biosciences files to sell 2.1M shares of common stock for holders

2025-10-20T21:30:12.000Z - 10 months ago

Cellectar Biosciences files to sell 2.1M shares of common stock for holders

Cellectar Biosciences Registration statement: Registration Filing

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Cellectar Biosciences Registration statement: Registration Filing

Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225

2025-10-14T12:36:26.000Z - 11 months ago

Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

Oct 14, 2025, 8:30 AM EDT - 11 months ago

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Sep 11, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Sep 9, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Sep 5, 2025, 8:45 AM EDT - 1 year ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Sep 3, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Aug 27, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Cellectar Biosciences Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q2 2025

Cellectar Biosciences Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings release: Q2 2025

Cellectar Biosciences Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Quarterly report: Q2 2025

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14, 2025, 7:19 AM EDT - 1 year ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Aug 7, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jul 1, 2025, 9:25 AM EDT - 1 year ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Cellectar Biosciences Registration statement: Registration Filing

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Registration statement: Registration Filing

Cellectar Biosciences and U.S.-based Nusano Enter IntoΒ Multi-Isotope Supply Agreement

Jun 26, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences and U.S.-based Nusano Enter IntoΒ Multi-Isotope Supply Agreement

Cellectar Biosciences Registration statement: Registration Filing

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Registration statement: Registration Filing

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 11, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Cellectar Biosciences Proxy statement: Proxy Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Proxy statement: Proxy Filing

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Jun 4, 2025, 8:05 AM EDT - 1 year ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Biosciences Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q1 2025

Cellectar Biosciences Earnings release: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings release: Q1 2025

Cellectar Biosciences Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Quarterly report: Q1 2025

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 7:05 AM EDT - 1 year ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

May 7, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 1 year ago

Cellectar Announces Plan to Explore Strategic Alternatives

Cellectar Biosciences Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Proxy statement: Proxy Filing

Cellectar Biosciences Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Proxy statement: Proxy Filing

Cellectar Biosciences Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Proxy statement: Proxy Filing

Cellectar Biosciences Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q4 2024

Cellectar Biosciences Earnings release: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings release: Q4 2024

Cellectar Biosciences Annual report: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Annual report: Q4 2024

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 13, 2025, 7:05 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Mar 5, 2025, 8:05 AM EST - 1 year ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Cellectar Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 12:00 PM EST - 1 year ago

Cellectar Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:05 AM EST - 1 year ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cellectar Biosciences Registration statement: Registration Filing

Jan 29, 2025, 7:00 AM EST - 1 year ago

Cellectar Biosciences Registration statement: Registration Filing

Cellectar Biosciences Transcript: Biotech Showcase 2025

Jan 14, 2025, 2:30 PM EST - 1 year ago

Cellectar Biosciences Transcript: Biotech Showcase 2025

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at UpcomingΒ Biotech Showcase during the JP Morgan Healthcare Conference

Jan 12, 2025, 6:00 PM EST - 1 year ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at UpcomingΒ Biotech Showcase during the JP Morgan Healthcare Conference

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Dec 10, 2024, 5:00 PM EST - 1 year ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 21, 2024, 8:00 AM EST - 1 year ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Cellectar Biosciences Earnings Call Transcript: Q3 2024

Nov 18, 2024, 8:30 AM EST - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q3 2024

Cellectar Biosciences Earnings release: Q3 2024

Nov 18, 2024, 8:30 AM EST - 1 year ago

Cellectar Biosciences Earnings release: Q3 2024

Cellectar Biosciences Quarterly report: Q3 2024

Nov 18, 2024, 8:30 AM EST - 1 year ago

Cellectar Biosciences Quarterly report: Q3 2024

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 18, 2024, 7:05 AM EST - 1 year ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 14, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 12, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 11, 2024, 4:05 PM EST - 1 year ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 7, 2024, 6:40 AM EST - 1 year ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Nov 1, 2024, 5:00 PM EDT - 1 year ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop onΒ Waldenstrom's Macroglobulinemia

Aug 26, 2024, 6:40 AM EDT - 2 years ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop onΒ Waldenstrom's Macroglobulinemia

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 23, 2024, 5:00 PM EDT - 2 years ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

Cellectar Biosciences Earnings Call Transcript: Q2 2024

Cellectar Biosciences Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

Cellectar Biosciences Quarterly report: Q2 2024

Cellectar Biosciences Earnings release: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

Cellectar Biosciences Earnings release: Q2 2024

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 13, 2024, 6:40 AM EDT - 2 years ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Aug 8, 2024, 5:15 PM EDT - 2 years ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

EvenBetter99
EvenBetter99 Sep. 6 at 11:31 AM
$CLRB Platform That Finds The β€œAchilles Heel” of Cancer Cells πŸ’ͺπŸ’ͺπŸ’ͺ
1 Β· Reply
EvenBetter99
EvenBetter99 Aug. 29 at 6:26 PM
$CLRB USD 200 per share is an easy target, Look at their radiopharma tech and pipeline ☝️πŸ’ͺπŸ’ͺπŸ’ͺ
3 Β· Reply
Sloan88
Sloan88 Aug. 27 at 12:41 PM
$CLRB I’m pretty sure I started a movementπŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ˜‚πŸ˜‚πŸ˜‚πŸ˜‚ #1sharepumpclubπŸš€πŸš€πŸš€πŸš€
2 Β· Reply
Sloan88
Sloan88 Aug. 25 at 6:30 PM
$CLRB if you see a $2.88 pop in the morning it’s most likely me makes me feel good for a few hoursπŸ€·πŸ»β€β™‚οΈπŸ€·πŸ»β€β™‚οΈπŸ€·πŸ»β€β™‚οΈplus I’m up over 100k last 60 days and now 10k share club memberπŸš€πŸš€πŸš€πŸš€πŸš€
2 Β· Reply
decdfinanz
decdfinanz Aug. 25 at 11:13 AM
$CLRB Anyone knowing why this is up 15% in pre-market? 🀨🧐
2 Β· Reply
EvenBetter99
EvenBetter99 Aug. 21 at 1:39 PM
$CLRB CLRB is a "Strong Buy." πŸš€πŸš€πŸš€ Its blood cancer drug brings joy with a 61.8% major response rate and 17.8 months of relief for patients.πŸ’ͺπŸ’ͺ Financially, it is incredibly safe. A massive $140M funding lifeline plus $34M cash in the bank fully funds operations into 2027. Wall Street adores this stock, predicting a beautiful 342% upside with an $11.50 target price.πŸš€πŸš€ With an FDA submission set for mid-2027, this company is a bright, winning choice!πŸ’ͺπŸ’ͺ
1 Β· Reply
Polaris2024
Polaris2024 Aug. 21 at 10:53 AM
$CLRB This company cannot get there act together. I have lost $100,000’s on this stock and the same scenario always plays out. Never gets through the FDA
0 Β· Reply
CantNameThatTune
CantNameThatTune Aug. 19 at 12:00 PM
$TNON $CLRB The point I was trying to make is... If CLRB has ALL that goodness going on with so many targets $10-$25 and still down under $3 then... TNON has no business being double digits
1 Β· Reply
CantNameThatTune
CantNameThatTune Aug. 19 at 11:46 AM
$TNON Sometimes I'm left to wonder what on earth people are possibly thinking. There is a stock $CLRB sitting on the cusp on Ph 2 results anytime that will give clear indication their current lead indication will be a "Best in World" treatment plan that will lead to immediate FDA approval. It has a dozen price targets from $10 - $25 What is TNON news? No new sales. Is anyone even buying Catamaran? $100 million shelf offering because no one is buying. It's the one running over $10? Huh?
0 Β· Reply
Sloan88
Sloan88 Aug. 14 at 7:44 PM
$CLRB we have a new Mag 7
2 Β· Reply
Sloan88
Sloan88 Aug. 14 at 6:36 PM
$CLRB that makes it 7 filings of 9.99% ownership πŸ‘€πŸ‘€πŸ‘€πŸ‘€πŸ‘€πŸ‘€ something is definitely going on behind the scenes πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€
1 Β· Reply
CantNameThatTune
CantNameThatTune Aug. 14 at 12:09 PM
$CLRB Bearish takeaway? Are you kidding me? They just improved net loss from $3.39 per share loss to 57 cents FOR AN 83% improvement! Additionally, THEY STRENGTHENED their cash position. They are all systems go for Phase 3 AND yet another 10% ownership filing last night. This time by a firm that seems to know stuff in advance.
0 Β· Reply
EvenBetter99
EvenBetter99 Aug. 14 at 5:33 AM
$CLRB 1. Europe (EMA) – The Near-Term PathwayStatus: Fully on track. Next Step: The submission of the Conditional Marketing Authorization (CMA) application is scheduled for Q3 2026 (within the next few weeks). Advantage: The European Medicines Agency (EMA) does not require any additional clinical studies prior to commercial launch. The European market launch is still targeted for early 2027. πŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺ
1 Β· Reply
EvenBetter99
EvenBetter99 Aug. 14 at 5:32 AM
$CLRB Global Strategy: While they seek Conditional Approval in Europe for 2027, they are simultaneously preparing a New Drug Application (NDA) for accelerated approval with the U.S. FDA in mid-2027, backed by a global Phase 3 confirmatory study that begins site activation this year. πŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺπŸ’ͺ
0 Β· Reply
CLRBtothemoon
CLRBtothemoon Aug. 13 at 8:02 PM
$CLRB can anyone tell me where the European conditional approval is? I have heard zero about that. οΏΌ
0 Β· Reply
Sloan88
Sloan88 Aug. 13 at 1:51 PM
$CLRB planning on releasing data of CLR 125 (TNBC) trail at San Antonio Breast Cancer Conference Dec 8-11 that is bullish as F$CK sounded really exciting about it in my opinion πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€
0 Β· Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 13 at 12:27 PM
$CLRB Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.57 up 83.19% YoY
0 Β· Reply
made006
made006 Aug. 13 at 11:42 AM
$CLRB how this liar not been sued is unbelievable ....not just moving the goal post now they don't even talk about Europe
0 Β· Reply
Sloan88
Sloan88 Aug. 12 at 5:52 PM
$CLRB anybody else listening to the call???? Tomorrow πŸ’°πŸ™πŸ’°πŸ™πŸ’°πŸ™
1 Β· Reply
Sloan88
Sloan88 Aug. 11 at 8:28 PM
$CLRB who’s ready for πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€
1 Β· Reply
EvenBetter99
EvenBetter99 Aug. 10 at 8:46 PM
$CLRB Buying now and sell at 50 or buying at 50 and sell at 100? πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€ 😎🀞
0 Β· Reply